Rd. Gordon et al., HIGH-INCIDENCE OF PRIMARY ALDOSTERONISM IN 199 PATIENTS REFERRED WITHHYPERTENSION, Clinical and experimental pharmacology and physiology, 21(4), 1994, pp. 315-318
1. This study sought to assess the incidence of primary aldosteronism
in 199 hypertensives who were normokalaemic and in whom the question o
f primary aldosteronism had never been raised. 2. The screening test a
pplied was the aldosterone to renin ratio in plasma, which was raised
in 40 and normal in 159 patients. A second ratio was normal in 14 of t
hese 40. 3. Twenty-two patients with two further raised ratios require
d fludrocortisone suppression testing. This has been completed in 17,
and failure to suppress led to a diagnosis of primary aldosteronism in
all. 4. A dexamethasone suppression test (DST) excluded ACTH-dependen
t hyperaldosteronism and laterality of aldosterone production was dete
rmined by adrenal vein sampling. 5. Unilaterality in five patients led
to adrenalectomy in four and spironolactone in one. Bilaterality in s
ix patients led to spironolactone. 6. This study so far provides a pro
ven (minimum) incidence for primary aldosteronism of 8.5%, a probable
incidence of 12.0% (including two raised ratios) and a possible (maxim
um) incidence of 13.0% (leaving out those with second ratio normal). E
xclusion of hypokalaemic hypertensives will lead to an underestimation
of the true incidence of primary aldosteronism. 7. Based on this and
other evidence, it is estimated that the incidence of primary aldoster
onism in the 'essential hypertensive' population is between 5 and 15%,
and is probably around 10%.